Our study also revealed that PARP1 depletion attenuated the changes in PARP inhibitors sensitivity after knockdown or overexpression of FBP1 in pancreatic cancer cells (Fig. S2A–D). This evidence concerns the gene PARP1 and familial pancreatic carcinoma.